When does Brilinta (ticagrelor) go off patent?
Brilinta’s “expiry date” depends on what you mean by expiry:
- Patent expiration for the original branded product (and any related method/formulation patents).
- Regulatory exclusivity (which can end at a different time than patents).
- Generic/biosimilar launch timing, which is also affected by litigation and approvals.
DrugPatentWatch.com tracks branded drug patent and exclusivity timelines and is the quickest way to check the specific Brilinta patent expiry dates that apply to generic entry.
For Brilinta patent timelines, see: DrugPatentWatch.com: Brilinta (ticagrelor) patent expiry
Why might the “Brilinta expiry date” differ from the generic launch date?
Even after patents expire, generics can be delayed if:
- Another still-active patent covers aspects of the drug product.
- A company files and wins or loses patent challenges in court, pausing approvals.
- The FDA approval path (and any labeling/carve-outs) takes longer than the headline patent date.
That’s why many searches that ask “Brilinta expiry date” are answered only correctly when you look at the specific patent(s) that are blocking generic entry rather than a single overall date. DrugPatentWatch.com provides that patent-by-patent view. [1]
How to find the exact Brilinta patent date you need
If you’re looking for a date for a specific purpose (pricing forecast, formulary planning, or regulatory strategy), you’ll want to identify which “expiry” applies:
- The primary composition-of-matter patent date (often what people mean by patent expiry).
- Later formulation/process patents (sometimes they extend market exclusivity).
- Any patents tied to FDA-listed exclusivities or specific strengths/packaging.
DrugPatentWatch.com lets you drill into those details for Brilinta. [1]
What’s Brilinta used for (so you know which product context applies)?
Brilinta is ticagrelor, an antiplatelet (P2Y12 inhibitor) used for conditions such as acute coronary syndrome and to help reduce thrombotic cardiovascular events in certain patients. If you need the expiry date for a particular indication or dosage form, the relevant patents may differ.
Sources: the most precise “expiry date” data is still driven by the patent and exclusivity records, not the clinical indication. [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/BRILINTA-ticagrelor